Bacteria constantly adapt how they operate in order to survive and thrive; biofilm creation is one particularly tenacious such adaptation. At Biophys, we understand this strategy of adaptation to survive and thrive and have adopted the same approach with our R&D activities that target more effective management of bacterial biofilms.
Our R&D focus on counteracting Antimicrobial Resistance (AMR) by developing antimicrobial compounds, medical devices incorporating antimicrobials and diagnostic tests for infectious diseases, means that we are proud to be able to collaborate with Disperazol Pharma (Denmark). Disperazol is a spinout from the University of Copenhagen (UCPH) and we are delighted to be part of the team to develop their second generation antibiofilm asset.
Biophys, with its expanding Class 2 microbiology laboratory, offers Disperazol Pharma a development opportunity to rapidly test its next generation assets to move from hit-to-lead to lead optimisation. Disperazol Pharma brings with it 40 years of biofilm expertise in the form of its CSO, Prof Michael Givskov, whose team at the Costerton Biofilm Center at UCPH in Denmark, developed the fundamental science to manipulate cyclic-di-nucleotide levels in bacterial cells in order to prevent biofilm formation or dismantle mature biofilms.
Biophys will start testing Disperazol Pharma’s new library of compounds using novel reporter strains of Pseudomonas aeruginosa and Escherichia coli from January 2026.